Clinical trial
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib…
NCT00171249 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00171249 |
|---|---|
| Title | An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia |
| Official title | An Extension to a Phase II Study to Determine the Safety and Anti-Leukemic Effects of STI571 in Adult Patients With Philadelphia Chromosome Positive Leukemia Including Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Accelerated Phase Chronic Myeloid Leukemia |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | STI571 400 mg, STI571 600 mg |
| Enrollment | 293 |
| Start date | Aug 9, 1999 |
| Primary completion | Sep 23, 2013 |
| Completion | Sep 23, 2013 |
| First posted | Sep 15, 2005 |
| Last update posted | Jul 22, 2021 |
| Countries | France, Germany, Italy, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: